The disease caused by the SARS-CoV-2 (COVID-19) coronavirus, which first officially appeared in China in December 2019, spread very quickly around the world and was the focus of health systems. Despite the pandemic, antimicrobial resistance remained a pressing global health problem that should not be ignored. Antimicrobial resistance is one of the biggest challenges facing modern medicine, especially in the newly emerging circumstances of a pandemic. There are many factors that influence resistance, some of which have changed during the pandemic. Hand hygiene and infection prevention procedures have been increased, international travel has been reduced and the number of routine hospital procedures has been reduced. Although COVID-19 is a viral disease, excessive consumption of antibiotics due to outpatient and hospital use of these drugs was observed early in the pandemic. It has long been known that the excessive use of antibiotics promotes the development of bacterial resistance to antibiotics. The fact is that less than 8% of patients with COVID-19 actually have a bacterial co-infection that occurs early in the course of the disease, but many patients received antibiotics unnecessarily. According to all guidelines, the use of antibiotics is not recommended unless there is a bacterial co-infection, especially if it is a mild form of the disease of COVID-19. Because of all of the above, it is necessary to revise antimicrobial therapy management programs, adapt them to the current, pandemic situation and use them in practice. Such programs have already proven to be effective in reducing antibiotic consumption and bacterial resistance, and can contribute to improving patient outcomes and reducing healthcare costs.